Literature DB >> 32303482

Re-emergence of SARS-CoV2 in a discharged COVID-19 case.

Mi Zhou1, Qingfeng Li1, Lin Cao1, Yingfen Liu1, Yi Zha1, He Xie2, Mingquan Zeng3, Xuemei Shi4, Yueqing Gao5, Liqiu Xie5, Mei Luo6, Yilan Zeng7.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32303482      PMCID: PMC7194673          DOI: 10.1016/j.jmii.2020.03.031

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


× No keyword cloud information.
Dear Editor: Since December 2019, novel coronavirus (SARS-CoV2) infected disease (now nominated as COVID-19) has soon emerged as a global health concern. However, information on the course of the disease is still limited. Here we report a case of COVID-19 who met the criteria for discharge but was tested positive for SARS-CoV2 again 10 days after discharge. The patient is a 40-year-old woman who had no baseline comorbidities, her disease course was illustrated in Fig. 1 A. She developed fever up to 37.8 °C on January 25th without other symptoms. 2 days later, she felt shortness of breath and developed diarrhea, and then went to local hospital. There her nasal swab was obtained, and SARS-CoV2 was tested positive with real-time reverse-transcriptase polymerase-chain-reaction (RT-PCR) assay targeting ORF1ab and N gene of virus genome. The patient was then transferred to our centre on day 5 of illness onset.
Figure 1

Clinical course of the patients. (A) Timeline for the clinical course in this patient and detection for SARS-CoV2; “+” and “−” indicates a positive or negative results for SARS-CoV2 by real-time RT-PCR assay, respectively; (B)–(D): Images of chest CT finds on day 6 (B), day 15 (C) and day 26 (D).

Clinical course of the patients. (A) Timeline for the clinical course in this patient and detection for SARS-CoV2; “+” and “−” indicates a positive or negative results for SARS-CoV2 by real-time RT-PCR assay, respectively; (B)–(D): Images of chest CT finds on day 6 (B), day 15 (C) and day 26 (D). Symptoms in this patient was mild throughout the hospitalization period. The patient received treatment including interferon α2b aerosol inhalation (5 million unit daily, day 5 - day 16), lopinavir/ritonavir tablets (400mg/100 mg, twice daily, day 7 - day 16) and supportive care in a negative-pressure isolation ward. On day 8, patient had a mild diarrhea (4 stools/day), but resolved soon after treatment with montmorillonite powder. Body temperature of the patient had returned normal since day 7. Oxygen saturation remained above 95% with low-flow (2–3L/min) oxygen supply. Initially, the patient had slight leukopenia and lymphopenia (0.71G/L, on day 5), but recovered soon (1.16G/L, on day 9). Chest computed tomography (CT) showed ground glass opacities (GGO) in the right lung at early phase (Fig. 1B), and then gradually changed to GGO with consolidation and fibrosis (Fig. 1C). By day 16, body temperature of this patient had retained normal for 9 days, and she complained no symptoms. RT-PCR examination for SARS-CoV-2 was performed on day 10, 11 and 14, and all 3 tests were negative. The patient was then discharged from hospital and was instructed to receive a quarantine at home. However, on day 24, the patient felt chest pain and had cough and sputum production. Her symptom was not relieved on day 25, so her nasal swab was obtained and the test for SARS-CoV-2 was positive again. The patient was admitted to our centre on day 26. Chest CT scan on day 26 showed absorption on lung disease (Fig. 1D). The observation of the patients is still ongoing. Family member of this patient has been ruled out from infection. Previous study on SARS-CoV showed that virus load could be detected for more than 10 weeks after disease onset. It is reasonable to suppose that SARS-CoV2 may also shed from patients for a prolonged duration. As the viral load in a sample may fluctuate during disease course, false negative results may also occur. Although it is not clear whether this positive finding is associated with disease transmission potential, given the disastrous outcome of disease transmission, longer observation period should be taken into consideration for COVID-19 patients.
  3 in total

1.  Viral load of SARS-CoV-2 in clinical samples.

Authors:  Yang Pan; Daitao Zhang; Peng Yang; Leo L M Poon; Quanyi Wang
Journal:  Lancet Infect Dis       Date:  2020-02-24       Impact factor: 25.071

2.  Laboratory diagnosis of SARS.

Authors:  Paul K S Chan; Wing-Kin To; King-Cheung Ng; Rebecca K Y Lam; Tak-Keung Ng; Rickjason C W Chan; Alan Wu; Wai-Cho Yu; Nelson Lee; David S C Hui; Sik-To Lai; Ellis K L Hon; Chi-Kong Li; Joseph J Y Sung; John S Tam
Journal:  Emerg Infect Dis       Date:  2004-05       Impact factor: 6.883

3.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

  3 in total
  3 in total

1.  A systematic review and meta-analysis of discharged COVID-19 patients retesting positive for RT-PCR.

Authors:  Xiangying Ren; Xiangge Ren; Jiaao Lou; Yongbo Wang; Qiao Huang; Yuexian Shi; Yuqing Deng; Xiaoyan Li; Liye Lu; Siyu Yan; Yunyun Wang; Lisha Luo; Xiantao Zeng; Xiaomei Yao; Yinghui Jin
Journal:  EClinicalMedicine       Date:  2021-04-17

Review 2.  Demand for longer quarantine period among common and uncommon COVID-19 infections: a scoping review.

Authors:  Zhi-Yao Li; Yu Zhang; Liu-Qing Peng; Rong-Rong Gao; Jia-Rui Jing; Jia-Le Wang; Bin-Zhi Ren; Jian-Guo Xu; Tong Wang
Journal:  Infect Dis Poverty       Date:  2021-04-26       Impact factor: 4.520

Review 3.  Laboratory diagnosis of COVID-19 in China: A review of challenging cases and analysis.

Authors:  Ran Jing; Timothy Kudinha; Meng-Lan Zhou; Meng Xiao; He Wang; Wen-Hang Yang; Ying-Chun Xu; Po-Ren Hsueh
Journal:  J Microbiol Immunol Infect       Date:  2020-10-17       Impact factor: 4.399

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.